What were the key takeaways from BioCryst Pharmaceuticals's earnings call?

What guidance did BioCryst Pharmaceuticals's management provide for the next earnings period?

Did BioCryst Pharmaceuticals beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for BioCryst Pharmaceuticals year over year?

What is BioCryst Pharmaceuticals's latest dividend and current dividend yield?

What were the key takeaways from BioCryst Pharmaceuticals’s earnings call?

What factors drove the changes in BioCryst Pharmaceuticals's revenue and profit?

What is BioCryst Pharmaceuticals's gross profit margin?

- **Revenue Surge**: ORLADEYO up 37% YoY to $159.1M, with U.S. sales dominating at 89%. Full-year guidance raised to $590-600M. 
- **Strategic Wins**: European sale & debt repayment; $400M Astria acquisition for navenibart. 
- **Pipeline Momentum**: BCX17725 skin penetration in healthy volunteers; DME program to be spun/partnered. 
- **Financial Strength**: $269M cash pre-close; 2025 non-GAAP net income positive. 
- **Pediatric Play**: 500 diagnosed pediatric HAE patients; PDUFA mid-Dec with payer alignment intact.

**【CEO Summary Section】**
- **ORLADEYO Revenue Growth**: Q3 revenue of $159.1M, up 37% YoY, driven by U.S. sales ($141.6M, 89% of total). Full-year guidance raised to $590-600M, with $1B peak by 2029. 
- **Strategic Transactions**: Sold European business, repaid $200M Pharmakon debt, and announced Astria acquisition (navenibart) for $400M in Q1 2026. 
- **Pipeline Progress**: BCX17725 (Netherton) shows skin penetration in healthy volunteers; DME program to be spun/partnered post-Q1 data. 
- **Leadership Transition**: Charlie Gayer to CEO, Ron Dullinger to lead U.S. commercial team.

**【CFO Financial Commentary】**
- **Financial Highlights**: Non-GAAP net income $35.6M (EPS $0.17), up 107% YoY. Cash $269M (pre-close of European sale). 
- **Cost Efficiency**: Operating expenses $118M (up 28% YoY), with R&D investment. 2025 guidance: $430-440M OpEx, positive cash flow. 
- **Liquidity**: $294M post-European sale; targeting $1B cash by 2029. 

**【Q&A Key Highlights】**
- **ORLADEYO Competition**: Retention rate stable at 60%, with 64 new prescribers Q3. Gross-to-net ~15%, stable through 2026. 
- **Pediatric Launch**: 500 diagnosed pediatric HAE patients, 40% untreated. PDUFA date mid-Dec; payer alignment similar to adult. 
- **DME Program**: Decision to de-prioritize due to cost and expertise; Phase I data pending. 
- **Netherton Progress**: BCX17725 shows skin penetration; Q1 2026 data from 10+ patients. SubQ/IV dosing exploration ongoing. 
- **Regulatory Updates**: FDA interactions stable despite shutdown; no PDUFA delay anticipated.

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

BCRX

BCRX fundamentals

You can ask Aime